18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE
Abhishek A. Solanki,Bital Savir-Baruch,Stanley L. Liauw,Jeff Michalski,Jonathan D. Tward,Neha Vapiwala,Eugene J. Teoh,LOCATE study group,Lee P. Adler,Gerald L. Andriole,Laurence H. Belkoff,Daniel Burzon,Albert Chau,Paul Dato,Fenghai Duan,Michael Farwell,Stephen Fogelson,Peter Gardiner,Lucy Hanna,John M. Hoffman,Charles Intenzo,David Josephson,Jed Kaminetsky,Michael Kipper,Lale Kostakoglu,Borys Krynyckyi,Karen E. Linder,Umar Mahmood,Helga Marques,David Mankoff,Jonathan McConathy,John Melnick,Matthew P. Miller,William Oh,Shaile Philips,Judith Rose,Bital Savir-Baruch,David M. Schuster,Barry A. Siegel,Daniel J. Stevens,Ashutosh Tewari,Przemyslaw Twardowski,Penelope Ward,Martha Wasserman,Sharon Weick,Jian Q. Yu,Jian Q. (Michael) Yu
DOI: https://doi.org/10.1016/j.prro.2020.05.007
IF: 3.439
2020-09-01
Practical Radiation Oncology
Abstract:PURPOSE: Conventional imaging rarely localizes the site(s) of prostate cancer recurrence in patients undergoing evaluation for salvage radiation therapy (sRT) after radical prostatectomy (RP). LOCATE (NCT02680041) was a prospective, multicenter study investigating the impact of <sup>18</sup>F-fluciclovine positron emission tomography and computed tomography (PET/CT) on the management of patients with biochemical recurrence of prostate cancer after curative-intent radiation or RP and negative or equivocal conventional imaging. Our objective was to determine the impact of <sup>18</sup>F-fluciclovine PET/CT on treatment decisions for men planning to undergo sRT for biochemical recurrence post-RP.METHODS AND MATERIALS: We conducted a subgroup analysis of post-RP patients enrolled in LOCATE who were planning to undergo sRT with or without hormonal therapy based on prescan documentation. <sup>18</sup>F-Fluciclovine PET/CT was performed according to standardized procedures. The treatment plan postscan was compared with the prescan plan, and Fisher exact test was used to determine the impact of prescan prostate-specific antigen (PSA) and Gleason sum (GS) on positivity and anatomic patterns of uptake.RESULTS: A total of 114 patients (median prescan PSA 0.42 [interquartile range, 0.3-1.1] ng/mL) met selection criteria (54% of patients in LOCATE). Forty-eight (42%) had <sup>18</sup>F-fluciclovine-avid lesions. Twelve patients (11%) had positive findings only in the prostate bed, 24 (21%) had positivity only in the pelvis (prostate bed or pelvic nodes), and 24 (21%) had extrapelvic findings. PSA >0.5 ng/mL and GS ≥8 were associated with a higher risk of extrapelvic positivity (P < .05). Postscan, 55 (48%) patients had a management change; 37 (32%) had a change in overall treatment approach (ie, omission of sRT); and 18 (16%) had sRT target modification.CONCLUSIONS: <sup>18</sup>F-Fluciclovine PET/CT is positive in nearly half of patients planning to undergo post-RP sRT with negative/equivocal conventional imaging, with findings frequently leading to changes in management. PSA >0.5 ng/mL and GS ≥8 are associated with a higher risk of extrapelvic positive findings.
oncology,radiology, nuclear medicine & medical imaging